Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

byMichael Horton

August 12, 2022

1 minute read

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

News
Tech

ChargePoint Granted U.S. Patent #:11524590: Automatic and dynamic home electricity load balancing for the purpose of EV charging

By Charles Gross

December 13, 12:42 PM

https://www.scribd.com/document/614183704/CHPT-Patent

CHPT

Oppenheimer Maintains Outperform on Citigroup, Lowers Price Target to $83

By Benzinga Newsdesk

January 17, 1:39 PM

Oppenheimer analyst Chris Kotowski maintains Citigroup (NYSE:C) with a Outperform and lowers the price target from $87 to $83.

Peter Schiff Spots Great Divergence In Gold, Bank Stocks: ‘Old Fortunes Will Be Lost And New Fortunes Will Be Made’

By Bhavik Nair

May 5, 1:46 AM

Peter Schiff, chief economist and global strategist at Euro Pacific Capital, has highlighted the contrarian price movements in…

GLD

Information Services Q3 EPS $0.14 Beats $0.10 Estimate, Sales $69.00M Miss $71.99M Estimate

By Benzinga Newsdesk

November 3, 5:18 PM

Information Services (NASDAQ:III) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.10 by 40 percent. This is a 16.67 percent increase over earnings of $0.12 per share from

III

Jasper Therapeutics Q2 EPS $(0.29)

Related Posts

ChargePoint Granted U.S. Patent #:11524590: Automatic and dynamic home electricity load balancing for the purpose of EV charging

Oppenheimer Maintains Outperform on Citigroup, Lowers Price Target to $83

Peter Schiff Spots Great Divergence In Gold, Bank Stocks: ‘Old Fortunes Will Be Lost And New Fortunes Will Be Made’

Information Services Q3 EPS $0.14 Beats $0.10 Estimate, Sales $69.00M Miss $71.99M Estimate